Illumina Inc. (NASDAQ:ILMN) is one of the 8 Best Quality Stocks to Buy According to Hedge Funds. Illumina Inc. (NASDAQ:ILMN) is one of the best quality stocks to buy according to hedge funds. On March ...

We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at where Illumina, Inc. (NASDAQ:ILMN) stands against the other immunotherapy ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

New algorithms support Illumina TruPath™ Genome: v4.5 introdues analytical support for TruPath, leveraging algorithmic advances to resolve 15 highly homologous, medically-relevant genes for rare ...

Expands pharma access to large omics datasets to advance target discovery and drug development SAN DIEGO, Oct. 1, 2025 /PRNewswire/ -- Illumina, Inc. (ILMN) today announced the launch of BioInsight, a ...

SAN DIEGO, June 23, 2025 /PRNewswire/ -- Illumina, Inc. (ILMN) announced today it has entered into a definitive agreement with Standard BioTools (LAB) under which Illumina will acquire SomaLogic, a ...

Diamond Hill Capital, an investment management company, released its “Mid Cap Strategy” investor letter for the first quarter of 2025. A copy of the letter can be downloaded here. The first quarter of ...

Combination leverages SomaScan with Illumina's NGS ecosystem, DRAGEN software, and Illumina Connected Multiomics to rapidly transform insights into discoveries SAN DIEGO, Jan. 30, 2026 /PRNewswire/ -- ...

Illumina Inc. (NASDAQ:ILMN) has agreed to pay $9.8 million to resolve allegations it knowingly sold genomic sequencing systems with cybersecurity vulnerabilities to several U.S. government agencies.

Investors in Illumina Inc (Symbol: ILMN) saw new options become available today, for the May 9th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ILMN options ...

Patient Capital Management, a value investing firm, released its “Patient Opportunity Equity Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. In Q4 2025, ...